{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.8","upperLimit":"22.8","value":"6.9"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"28.7","value":"5.9"},{"groupId":"OG002","lowerLimit":"3.4","upperLimit":"16.4","value":"8.3"},{"groupId":"OG003","lowerLimit":"3.3","upperLimit":"21.4","value":"9.8"},{"groupId":"OG004","lowerLimit":"0.7","upperLimit":"20.2","value":"6.1"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.8","upperLimit":"35.8","value":"17.2"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"28.7","value":"5.9"},{"groupId":"OG002","lowerLimit":"16.2","upperLimit":"35.6","value":"25.0"},{"groupId":"OG003","lowerLimit":"20.8","upperLimit":"47.9","value":"33.3"},{"groupId":"OG004","lowerLimit":"3.4","upperLimit":"28.2","value":"12.1"}]}],"title":"24 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.8","upperLimit":"35.8","value":"17.2"},{"groupId":"OG001","lowerLimit":"1.5","upperLimit":"36.4","value":"11.8"},{"groupId":"OG002","lowerLimit":"19.2","upperLimit":"39.5","value":"28.6"},{"groupId":"OG003","lowerLimit":"20.8","upperLimit":"47.9","value":"33.3"},{"groupId":"OG004","lowerLimit":"9.0","upperLimit":"38.9","value":"21.2"}]}],"title":"36 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.3","upperLimit":"43.5","value":"24.1"},{"groupId":"OG001","lowerLimit":"1.5","upperLimit":"36.4","value":"11.8"},{"groupId":"OG002","lowerLimit":"24.5","upperLimit":"45.7","value":"34.5"},{"groupId":"OG003","lowerLimit":"29.3","upperLimit":"57.8","value":"43.1"},{"groupId":"OG004","lowerLimit":"9.0","upperLimit":"38.9","value":"21.2"}]}],"title":"48 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.3","upperLimit":"43.5","value":"24.1"},{"groupId":"OG001","lowerLimit":"1.5","upperLimit":"36.4","value":"11.8"},{"groupId":"OG002","lowerLimit":"29.9","upperLimit":"51.7","value":"40.5"},{"groupId":"OG003","lowerLimit":"32.9","upperLimit":"61.5","value":"47.1"},{"groupId":"OG004","lowerLimit":"15.6","upperLimit":"48.7","value":"30.3"}]}],"title":"60 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.3","upperLimit":"43.5","value":"24.1"},{"groupId":"OG001","lowerLimit":"1.5","upperLimit":"36.4","value":"11.8"},{"groupId":"OG002","lowerLimit":"31.0","upperLimit":"52.9","value":"41.7"},{"groupId":"OG003","lowerLimit":"34.8","upperLimit":"63.4","value":"49.0"},{"groupId":"OG004","lowerLimit":"15.6","upperLimit":"48.7","value":"30.3"}]}],"title":"72 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.3","upperLimit":"43.5","value":"24.1"},{"groupId":"OG001","lowerLimit":"1.5","upperLimit":"36.4","value":"11.8"},{"groupId":"OG002","lowerLimit":"32.1","upperLimit":"54.1","value":"42.9"},{"groupId":"OG003","lowerLimit":"34.8","upperLimit":"63.4","value":"49.0"},{"groupId":"OG004","lowerLimit":"18.0","upperLimit":"51.8","value":"33.3"}]}],"title":"84 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.7","upperLimit":"47.2","value":"27.6"},{"groupId":"OG001","lowerLimit":"1.5","upperLimit":"36.4","value":"11.8"},{"groupId":"OG002","lowerLimit":"32.1","upperLimit":"54.1","value":"42.9"},{"groupId":"OG003","lowerLimit":"34.8","upperLimit":"63.4","value":"49.0"},{"groupId":"OG004","lowerLimit":"18.0","upperLimit":"51.8","value":"33.3"}]}],"title":"90 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"84"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"33"}],"units":"Participants"}],"description":"Molecular response will be assessed using BCR-ABL transcript levels measurement by real-time quantitative polymerase chain reaction (qPCR). (CMR) is defined as absence of BCR-ABL rearrangements by real-time qPCR analysis. The percentage of treated participants with CMR is reported by arm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Children and adolescents with CP-CML who were resistant or intolerant to imatinib received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG000","title":"Cohort 1"},{"description":"Children and adolescents with Ph+ ALL, AP-CML or BP-CML who were resistant or intolerant to, or relapsed after imatinib therapy received dasatinib tablets at a dose schedule of 80 mg/m2 QD on a continuous oral regimen.","id":"OG001","title":"Cohort 2"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD or powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG002","title":"Cohort 3"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG003","title":"Cohort 3a"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG004","title":"Cohort 3b"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"90 months","title":"Complete Molecular Response (CMR) Rate up to 7.5 Years","type":"SECONDARY","unitOfMeasure":"percentage of participants"}